EP0681787B1 - Use of an enzyme for manufacturing an agent for the treatment and/or prophylaxis of coccidiosis - Google Patents
Use of an enzyme for manufacturing an agent for the treatment and/or prophylaxis of coccidiosis Download PDFInfo
- Publication number
- EP0681787B1 EP0681787B1 EP95106817A EP95106817A EP0681787B1 EP 0681787 B1 EP0681787 B1 EP 0681787B1 EP 95106817 A EP95106817 A EP 95106817A EP 95106817 A EP95106817 A EP 95106817A EP 0681787 B1 EP0681787 B1 EP 0681787B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- feed
- enzyme
- coccidiosis
- wheat
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 208000003495 Coccidiosis Diseases 0.000 title claims description 21
- 206010023076 Isosporiasis Diseases 0.000 title claims description 21
- 238000004519 manufacturing process Methods 0.000 title claims description 8
- 238000011321 prophylaxis Methods 0.000 title claims description 5
- 238000011282 treatment Methods 0.000 title claims description 5
- 108090000790 Enzymes Proteins 0.000 title description 44
- 102000004190 Enzymes Human genes 0.000 title description 44
- 241000209140 Triticum Species 0.000 claims description 28
- 235000021307 Triticum Nutrition 0.000 claims description 28
- 241001465754 Metazoa Species 0.000 claims description 26
- 101710121765 Endo-1,4-beta-xylanase Proteins 0.000 claims description 20
- 235000013339 cereals Nutrition 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 108010089934 carbohydrase Proteins 0.000 claims description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 5
- 235000019733 Fish meal Nutrition 0.000 claims description 4
- 239000004467 fishmeal Substances 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108010059892 Cellulase Proteins 0.000 claims description 3
- 229940106157 cellulase Drugs 0.000 claims description 3
- 108010082495 Dietary Plant Proteins Proteins 0.000 claims description 2
- 108010059820 Polygalacturonase Proteins 0.000 claims description 2
- 102000004139 alpha-Amylases Human genes 0.000 claims description 2
- 108090000637 alpha-Amylases Proteins 0.000 claims description 2
- 229940024171 alpha-amylase Drugs 0.000 claims description 2
- 108010093305 exopolygalacturonase Proteins 0.000 claims description 2
- 230000000153 supplemental effect Effects 0.000 claims 1
- 229940088598 enzyme Drugs 0.000 description 42
- 235000005911 diet Nutrition 0.000 description 28
- 230000037213 diet Effects 0.000 description 28
- 208000015181 infectious disease Diseases 0.000 description 19
- 230000003902 lesion Effects 0.000 description 18
- 230000001165 anti-coccidial effect Effects 0.000 description 14
- 239000003814 drug Substances 0.000 description 14
- 241000287828 Gallus gallus Species 0.000 description 13
- 229940079593 drug Drugs 0.000 description 13
- 230000037396 body weight Effects 0.000 description 12
- UHZZMRAGKVHANO-UHFFFAOYSA-M chlormequat chloride Chemical compound [Cl-].C[N+](C)(C)CCCl UHZZMRAGKVHANO-UHFFFAOYSA-M 0.000 description 12
- 235000019786 weight gain Nutrition 0.000 description 12
- 229940124536 anticoccidial agent Drugs 0.000 description 11
- 239000003224 coccidiostatic agent Substances 0.000 description 11
- 210000003250 oocyst Anatomy 0.000 description 11
- 240000007165 Eragrostis tenella Species 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 241000223931 Eimeria acervulina Species 0.000 description 9
- 244000144977 poultry Species 0.000 description 9
- 235000013594 poultry meat Nutrition 0.000 description 9
- 241000271566 Aves Species 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- WQGJEAMPBSZCIF-HKSLRPGUSA-N Maduramicin Chemical compound N.O1[C@@H](C)[C@H](OC)[C@@H](OC)C[C@H]1O[C@@H]1[C@H]([C@@]2(C)O[C@H](CC2)[C@@]2(C)O[C@]3(O[C@@H]([C@H](C)[C@@H](O)C3)[C@@H](C)[C@H]3[C@@H]([C@@H](OC)[C@H](C)[C@@](O)(CC(O)=O)O3)OC)CC2)O[C@@H]([C@@H]2[C@H](C[C@@H](C)[C@@](C)(O)O2)C)C1 WQGJEAMPBSZCIF-HKSLRPGUSA-N 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 241000223262 Trichoderma longibrachiatum Species 0.000 description 6
- 235000013330 chicken meat Nutrition 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 244000087226 Conyza maxima Species 0.000 description 5
- 240000008042 Zea mays Species 0.000 description 5
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 5
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 235000009973 maize Nutrition 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 244000005700 microbiome Species 0.000 description 5
- 241000272517 Anseriformes Species 0.000 description 4
- 101710130006 Beta-glucanase Proteins 0.000 description 4
- 241000223924 Eimeria Species 0.000 description 4
- 235000021050 feed intake Nutrition 0.000 description 4
- 244000045947 parasite Species 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 230000009469 supplementation Effects 0.000 description 4
- 235000004977 Brassica sinapistrum Nutrition 0.000 description 3
- 235000019764 Soybean Meal Nutrition 0.000 description 3
- 235000013601 eggs Nutrition 0.000 description 3
- 244000144992 flock Species 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 244000144972 livestock Species 0.000 description 3
- 235000013372 meat Nutrition 0.000 description 3
- 238000003307 slaughter Methods 0.000 description 3
- 239000004455 soybean meal Substances 0.000 description 3
- 235000007319 Avena orientalis Nutrition 0.000 description 2
- 244000075850 Avena orientalis Species 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 235000014698 Brassica juncea var multisecta Nutrition 0.000 description 2
- 235000006008 Brassica napus var napus Nutrition 0.000 description 2
- 235000006618 Brassica rapa subsp oleifera Nutrition 0.000 description 2
- 244000188595 Brassica sinapistrum Species 0.000 description 2
- 240000005979 Hordeum vulgare Species 0.000 description 2
- 235000007340 Hordeum vulgare Nutrition 0.000 description 2
- VHKXXVVRRDYCIK-CWCPJSEDSA-N Narasin Chemical compound C[C@H]1C[C@H](C)[C@H]([C@@H](CC)C(O)=O)O[C@H]1[C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)[C@@H]1[C@@H](C)C[C@@H](C)[C@@]2(C=C[C@@H](O)[C@@]3(O[C@@](C)(CC3)[C@@H]3O[C@@H](C)[C@@](O)(CC)CC3)O2)O1 VHKXXVVRRDYCIK-CWCPJSEDSA-N 0.000 description 2
- VHKXXVVRRDYCIK-UHFFFAOYSA-N Narasin Natural products CC1CC(C)C(C(CC)C(O)=O)OC1C(C)C(O)C(C)C(=O)C(CC)C1C(C)CC(C)C2(C=CC(O)C3(OC(C)(CC3)C3OC(C)C(O)(CC)CC3)O2)O1 VHKXXVVRRDYCIK-UHFFFAOYSA-N 0.000 description 2
- UKHWDRMMMYWSFL-UHFFFAOYSA-N Nicarbazin Chemical compound CC=1C=C(C)NC(=O)N=1.C1=CC([N+](=O)[O-])=CC=C1NC(=O)NC1=CC=C([N+]([O-])=O)C=C1 UKHWDRMMMYWSFL-UHFFFAOYSA-N 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 241000286209 Phasianidae Species 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 235000007238 Secale cereale Nutrition 0.000 description 2
- 244000082988 Secale cereale Species 0.000 description 2
- 240000006394 Sorghum bicolor Species 0.000 description 2
- 235000011684 Sorghum saccharatum Nutrition 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 235000019714 Triticale Nutrition 0.000 description 2
- 210000001198 duodenum Anatomy 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 229960001851 narasin Drugs 0.000 description 2
- 229940073485 nicarbazin Drugs 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 210000003046 sporozoite Anatomy 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 241000228158 x Triticosecale Species 0.000 description 2
- MOOFYEJFXBSZGE-QJUDHZBZSA-N 1,2-bis[(z)-(4-chlorophenyl)methylideneamino]guanidine Chemical compound C=1C=C(Cl)C=CC=1\C=N/N=C(/N)N\N=C/C1=CC=C(Cl)C=C1 MOOFYEJFXBSZGE-QJUDHZBZSA-N 0.000 description 1
- ZSZFUDFOPOMEET-UHFFFAOYSA-N 2-(4-chlorophenyl)-2-[2,6-dichloro-4-(3,5-dioxo-1,2,4-triazin-2-yl)phenyl]acetonitrile Chemical compound C1=CC(Cl)=CC=C1C(C#N)C1=C(Cl)C=C(N2C(NC(=O)C=N2)=O)C=C1Cl ZSZFUDFOPOMEET-UHFFFAOYSA-N 0.000 description 1
- 241000224482 Apicomplexa Species 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000194110 Bacillus sp. (in: Bacteria) Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 240000002791 Brassica napus Species 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- ZDPIZLCVJAAHHR-UHFFFAOYSA-N Clopidol Chemical compound CC1=NC(C)=C(Cl)C(O)=C1Cl ZDPIZLCVJAAHHR-UHFFFAOYSA-N 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 241000224483 Coccidia Species 0.000 description 1
- XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- ZEFNOZRLAWVAQF-UHFFFAOYSA-N Dinitolmide Chemical compound CC1=C(C(N)=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O ZEFNOZRLAWVAQF-UHFFFAOYSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000499566 Eimeria brunetti Species 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000223198 Humicola Species 0.000 description 1
- 229930182504 Lasalocid Natural products 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 229930191564 Monensin Natural products 0.000 description 1
- GAOZTHIDHYLHMS-UHFFFAOYSA-N Monensin A Natural products O1C(CC)(C2C(CC(O2)C2C(CC(C)C(O)(CO)O2)C)C)CCC1C(O1)(C)CCC21CC(O)C(C)C(C(C)C(OC)C(C)C(O)=O)O2 GAOZTHIDHYLHMS-UHFFFAOYSA-N 0.000 description 1
- 241000233892 Neocallimastix Species 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 235000019779 Rapeseed Meal Nutrition 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000192031 Ruminococcus Species 0.000 description 1
- KQXDHUJYNAXLNZ-XQSDOZFQSA-N Salinomycin Chemical compound O1[C@@H]([C@@H](CC)C(O)=O)CC[C@H](C)[C@@H]1[C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)[C@@H]1[C@@H](C)C[C@@H](C)[C@@]2(C=C[C@@H](O)[C@@]3(O[C@@](C)(CC3)[C@@H]3O[C@@H](C)[C@@](O)(CC)CC3)O2)O1 KQXDHUJYNAXLNZ-XQSDOZFQSA-N 0.000 description 1
- 239000004189 Salinomycin Substances 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 241000223259 Trichoderma Species 0.000 description 1
- LCTXBFGHZLGBNU-UHFFFAOYSA-M amprolium Chemical compound [Cl-].NC1=NC(CCC)=NC=C1C[N+]1=CC=CC=C1C LCTXBFGHZLGBNU-UHFFFAOYSA-M 0.000 description 1
- 229960003683 amprolium Drugs 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940031567 attenuated vaccine Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 229960000731 clopidol Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 229960000248 diclazuril Drugs 0.000 description 1
- 229960003934 dinitolmide Drugs 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000003640 drug residue Substances 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 208000026500 emaciation Diseases 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- LVASCWIMLIKXLA-LSDHHAIUSA-N halofuginone Chemical compound O[C@@H]1CCCN[C@H]1CC(=O)CN1C(=O)C2=CC(Cl)=C(Br)C=C2N=C1 LVASCWIMLIKXLA-LSDHHAIUSA-N 0.000 description 1
- 229950010152 halofuginone Drugs 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000002555 ionophore Substances 0.000 description 1
- 230000000236 ionophoric effect Effects 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- BBMULGJBVDDDNI-OWKLGTHSSA-N lasalocid Chemical compound C([C@@H]1[C@@]2(CC)O[C@@H]([C@H](C2)C)[C@@H](CC)C(=O)[C@@H](C)[C@@H](O)[C@H](C)CCC=2C(=C(O)C(C)=CC=2)C(O)=O)C[C@](O)(CC)[C@H](C)O1 BBMULGJBVDDDNI-OWKLGTHSSA-N 0.000 description 1
- 229960000320 lasalocid Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229960005358 monensin Drugs 0.000 description 1
- GAOZTHIDHYLHMS-KEOBGNEYSA-N monensin A Chemical compound C([C@@](O1)(C)[C@H]2CC[C@@](O2)(CC)[C@H]2[C@H](C[C@@H](O2)[C@@H]2[C@H](C[C@@H](C)[C@](O)(CO)O2)C)C)C[C@@]21C[C@H](O)[C@@H](C)[C@@H]([C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O2 GAOZTHIDHYLHMS-KEOBGNEYSA-N 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000004456 rapeseed meal Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 229960004591 robenidine Drugs 0.000 description 1
- 229960001548 salinomycin Drugs 0.000 description 1
- 235000019378 salinomycin Nutrition 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01006—Endo-1,3(4)-beta-glucanase (3.2.1.6)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/189—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01001—Alpha-amylase (3.2.1.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01004—Cellulase (3.2.1.4), i.e. endo-1,4-beta-glucanase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01015—Polygalacturonase (3.2.1.15)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01032—Xylan endo-1,3-beta-xylosidase (3.2.1.32), i.e. endo-1-3-beta-xylanase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21014—Microbial serine proteases (3.4.21.14)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S426/00—Food or edible material: processes, compositions, and products
- Y10S426/807—Poultry or ruminant feed
Definitions
- the present invention relates to the use of certain enzymes for the manufacture of an agent for the treatment and/or prophylaxis of coccidiosis.
- Coccidiosis is a common cause of disease in intensively-reared farm livestock, particularly in poultry. Coccidiosis is caused by a protozoa, a single-celled parasite, of the subphylum Apicomplexa . Many of the species that cause the disease in domestic animals belong to the genus Eimeria . The parasites multiply in the epithelium of the intestine. In chickens, seven species of Eimeria have been described, five of which are considered to be pathogenic. These are E. acervulina , E . maxima , E. necratrix, E . tenella and E . brunetti .
- Coccidia are ubiquitous organisms and are generally endemic wherever chickens are raised. Outbreaks of disease can vary from severe to very mild infections. Like many parasitic protozoa, the life cycle of the Eimeria is relatively complex. Sexual and asexual multiplication occurs within the chickens' intestines. During this process of multiplication and development of the parasite, the host tissue is destroyed which leads to the various clinical manifestations observed in outbreaks of coccidiosis. The oocysts produced and excreted develop further outside the host where they may undergo further development and infect other chickens. Oocysts can in fact survive outside the host for a long period of time which enables them to infect subsequent crops of birds. They may also be spread between flocks by other agents including people, pets, insects, rodents, dust and other birds.
- Sporulated oocysts contain four sporocysts, each containing two sporozoites. These sporozoites are released by mechanical and enzymatical action in the digestive tract of the chicken. This enables them to invade the epithelial cells in the intestine or caeca depending on the Eimera species involved.
- the overall symptoms may be one or more of the following: bloody droppings, high mortality, general lethargy, emaciation, a marked drop in feed consumption, diarrhoea and a drop in egg production. It has been estimated that coccidiosis is probably responsible for around 6-10% of unwanted mortality among poultry flocks. Additionally, subclinical disease increases Feed Conversion Ratios and lowers performance. Accordingly, the economic consequences of this disease are considerable.
- coccidiosis in poultry is routinely controlled by the use of preventive anticoccidial drug programmes.
- Such programmes attempt to restrict coccidial infections thus limiting the effects of subclinical outbreaks of disease.
- This is usually accomplished by the continuous inclusion of anticoccidial agents in the feed from early in the life of the flock until close to slaughter for broiler birds or by controlled withdrawal for layers. When first developed, such agents were used individually. This often resulted in strains of parasites developing drug-resistance.
- It is presently attempted to control coccidiosis by the continual introduction of new drugs or by the use of drug programmes involving rotational use of anticoccidial agents of different biochemical structures either during the grow-out period (shuttle programmes) or at frequent intervals (rotation programmes).
- WO 93/13786 discloses a formulation of micro-organisms suitable for administration to an animal.
- the formulation comprises a first micro-organism capable of producing lactic acid in the gastrointestinal tract of the animal, a second micro-organism capable of producing a bactericide to which the other micro-organisms in the formulation are resistant, and a fibre-digesting enzyme or a micro-organism capable of producing a fibre-digesting enzyme such as arabinase and xylanase.
- an object of the present invention is to provide a fresh class of compounds which can be used for the treatment and/or prophylaxis of coccidiosis.
- the present invention provides the use of a carbohydrase for the manufacture of an agent for the treatment and/or prophylaxis of coccidiosis.
- one or more carbohydrases may be included in the diet of an animal together with a conventional concentration of anticoccidial drugs. It has been found that this combination gives rise to a particularly advantageous synergy in that the resulting anticoccidial effect is greater than the mere addition of the individual effects of the enzyme(s) and anticoccidial drugs used separately.
- the enzyme can be formulated as a pre-mix together with any other enzymes to be included in the feed.
- the pre-mix can be added to the raw materials before feed manufacture, during feed manufacture or as a final step once the feed is otherwise ready for use. It is also possible to add the enzyme directly as a liquid to a feed material preformed as pellets or as a mash.
- the enzyme in the animal's diet by incorporating it into a second (and different) feed or drinking water which the animal also has access to. Accordingly, it is not essential that the enzyme is incorporated into the feed itself, although such incorporation forms a particularly preferred aspect of the present invention.
- the cereal can be any one or more of wheat, rye, triticale, barley, oats, sorghum, rice and maize. It is particularly preferred that the cereal is wheat.
- the cereal component of a cereal-based diet constitutes a source of protein
- sources of supplementary protein such as those derived from fishmeal, meatmeal or vegetables.
- sources of supplementary protein can constitute up to 50% by weight of the animal feed.
- Sources of vegetable proteins include at least one of full fat soybeans, rapeseed, canola, soybean meal, rapeseed meal and canola meal.
- the enzyme is incorporated into the feed, then this is preferably done in a relative amount of 0.00001-10 g of the enzyme protein per kilo of the feed; more preferably 0.0001-1 g/kg; and most preferably 0.001-0.1 g/kg.
- the enzyme used is a carbohydrase
- this is preferably a polysaccharidase such as a xylanase, a cellulase, an ⁇ -amylase or a pectinase.
- a preferred cellulase is ⁇ -glucanase.
- the polysaccharidase is a xylanase
- this may be obtained from a fungal source such as Trichoderma , Aspergillus , Humicola or Neocallimastix .
- the xylanase is the low pI xylanase and/or the high pI xylanase obtainable from Trichoderma longibrachiatum such as described in WO 92/06209.
- the xylanase can also be obtained from a bacterium such as Bacillus , Streptomyces , Clostridium or Ruminococcus .
- the xylanase may be obtained from a host which has been subjected to genetic manipulation such as by the inclusion of an appropriate gene within a host bacterial or fungal strain.
- the therapeutic agent does not include any non-enzymic anticoccidial agent.
- a conventional anticoccidial agent such as salinomycin, monensin, narasin, lasalocid, nicarbazin, maduramycin, nicarbazin and narasin in combination, diclazuril, dinitolmide, halofuginone, robenidine, amprolium or clopidol can be used.
- non-enzymic anticoccidial agents can be included in an animal feed preferably in an amount of 0-100 ppm, and more preferably 0-50 ppm. The latter amount in particular is well below the normal amounts of 50-200 ppm used for the majority of anticoccidial agents included in animal feeds.
- the agent provided by the present invention is in the form of an animal feed.
- a suitable feed can be obtained by preparing a pre-mix of the carbohydrase on a cereal carrier, and then adding an appropriate amount, e.g. 1 part by weight, of this pre-mix to 1000 parts by weight of a conventional animal feed.
- Coccidiosis can be treated or prevented in accordance with the present invention in a variety of livestock.
- the enzyme of the present invention can be provided in the form of an agent, such as an animal feed, to livestock such as chicken, turkeys, geese, ducks, pigs, sheep or cattle. It is however particularly preferred that the agent is administered to broiler chickens.
- A-D Four separate groups (A-D), each consisting of ten female Lohmann Brown chicks, were fed the following maize/wheat-based diet for their first twelve days of life: Maize/wheat-based diet Wheat 25% by weight Maize 42% by weight Soybean meal 20% by weight Fishmeal 10% by weight Vitamin and Mineral Mixture 3% by weight
- the diet of the chicks in the groups C and D was supplemented by an enzyme mix including xylanase obtained from Trichoderma Longibrachiatum and ⁇ -glucanase also obtained from Trichoderma Longibrachiatum .
- a pre-mix containing crude xylanase and crude ⁇ -glucanase was prepared and coated on a cereal carrier. This was then added to the above wheat-based feed such that the resulting feeds comprised about 0.0025 g of xylanase protein and about 0.005 g of ⁇ -glucanase protein per kg of feed.
- the diets fed to the chicks in groups A and B were not supplemented with enzymes.
- the chicks in groups B and D were infected with oocysts on day 14. This infection took the form of 5000 E. tenella and 50000 E. acervulina oocysts per chick. The chicks in groups A and C were not infected.
- E-H Four groups (E-H), each consisting of twenty Ross male broiler chicks were fed the wheat-based diet set out in the above Example 1 for their first twenty-eight days.
- the diets of the chicks in groups F and H were supplemented with xylanase obtained from Trichoderma Longibrachiatum .
- xylanase obtained from Trichoderma Longibrachiatum .
- a pre-mix containing crude xylanase was prepared and coated on a cereal carrier. This was then added to the above wheat-based feed such that the resulting feeds comprised about 0.0025 g of xylanase protein per kg of feed.
- the diets fed to the chicks in groups E and G were not supplemented with xylanase.
- the chicks in groups G and H were infected with oocysts on day 14 in the same manner as the groups B and D were infected in the above Example 1.
- the FCR of a feed is the ratio of the amount of feed consumed relative to the weight gain of the animal.
- a low FCR indicates that a given amount of feed results in a growing animal gaining proportionately more weight. This means that the animal is able to utilise the feed more efficiently.
- Enzyme addition numerically has a significant impact on the FCR results in Table 2.
- the FCR is improved by about 19% in the case of infected birds whose diets are supplemented by the enzymes.
- the FCR of the chicks whose diets are supplemented by enzymes improves only by 8.5% compared to the chicks in the group whose diets are not so supplemented.
- the feed provided to Group I is the initial wheat-based feed.
- the feeds provided to Groups J and L are each supplemented with 5 ppm of Maduramycin (the recommended level of inclusion) which is an anti-coccidial ionophore marketed as Cygro by Cyanamid.
- the enzyme which is included in each of the feeds provided to Groups K and L is a xylanase obtained from Trichoderma longibrachiatum . This is added as a pre-mix, which contains 0.375% of xylanase protein, to the feed in an amount of 0.6 g of the pre-mix per kg of the feed.
- lesion scores for E. acervulina were significantly lower for groups whose feeds were supplemented with the enzyme as compared to the closest comparable control groups.
- the inclusion of the enzyme in the feeds improved the lesion scores and also gave rise to a further improvement when used in combination with the anti-coccidial agent.
- the lesion scores caused by E . tenella did not improve on enzyme supplementation alone compared to the unsupplemented wheat diet.
- the presence of the enzyme did significantly improve the performance of the anti-coccidial agent as can be seen from a comparison between Groups J+ and L+.
- the feed of Group N was the initial wheat-based diet without any supplementation.
- the feed of Group M was the same feed supplemented with a xylanase enzyme obtained from Trichoderma longibrachiatum . This enzyme was added as a pre-mix containing 0.187 % of xylanase protein to the feed in an amount of 1 g of the pre-mix per kg of the feed.
- the pre-mix also included a protease obtained from Bacillus sp . This is present in the pre-mix in an amount of 0.06% of protease protein.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Animal Husbandry (AREA)
- Fodder In General (AREA)
- Feed For Specific Animals (AREA)
- General Preparation And Processing Of Foods (AREA)
Description
- The present invention relates to the use of certain enzymes for the manufacture of an agent for the treatment and/or prophylaxis of coccidiosis.
- Coccidiosis is a common cause of disease in intensively-reared farm livestock, particularly in poultry. Coccidiosis is caused by a protozoa, a single-celled parasite, of the subphylum Apicomplexa. Many of the species that cause the disease in domestic animals belong to the genus Eimeria. The parasites multiply in the epithelium of the intestine. In chickens, seven species of Eimeria have been described, five of which are considered to be pathogenic. These are E. acervulina, E. maxima, E. necratrix, E. tenella and E. brunetti.
- Coccidia are ubiquitous organisms and are generally endemic wherever chickens are raised. Outbreaks of disease can vary from severe to very mild infections. Like many parasitic protozoa, the life cycle of the Eimeria is relatively complex. Sexual and asexual multiplication occurs within the chickens' intestines. During this process of multiplication and development of the parasite, the host tissue is destroyed which leads to the various clinical manifestations observed in outbreaks of coccidiosis. The oocysts produced and excreted develop further outside the host where they may undergo further development and infect other chickens. Oocysts can in fact survive outside the host for a long period of time which enables them to infect subsequent crops of birds. They may also be spread between flocks by other agents including people, pets, insects, rodents, dust and other birds.
- Sporulated oocysts contain four sporocysts, each containing two sporozoites. These sporozoites are released by mechanical and enzymatical action in the digestive tract of the chicken. This enables them to invade the epithelial cells in the intestine or caeca depending on the Eimera species involved.
- Although there are differences in pathogenicity between species and strains of Eimeria, the overall symptoms may be one or more of the following: bloody droppings, high mortality, general lethargy, emaciation, a marked drop in feed consumption, diarrhoea and a drop in egg production. It has been estimated that coccidiosis is probably responsible for around 6-10% of unwanted mortality among poultry flocks. Additionally, subclinical disease increases Feed Conversion Ratios and lowers performance. Accordingly, the economic consequences of this disease are considerable.
- Various methods have been tried in an attempt to combat coccidiosis. Attempts have been made to control the disease through management strategies based on high standards of hygiene together with the use of chemical disinfectants in the environment of the poultry. However, even under extremely high hygienic conditions, it has not been found possible to eradicate coccidiosis although such measures were found to lower the initial infection pressure in a poultry house. Both live and attenuated vaccines have been investigated as methods of control, but these have only recently become available and are relatively expensive.
- At present, coccidiosis in poultry is routinely controlled by the use of preventive anticoccidial drug programmes. Such programmes attempt to restrict coccidial infections thus limiting the effects of subclinical outbreaks of disease. This is usually accomplished by the continuous inclusion of anticoccidial agents in the feed from early in the life of the flock until close to slaughter for broiler birds or by controlled withdrawal for layers. When first developed, such agents were used individually. This often resulted in strains of parasites developing drug-resistance. It is presently attempted to control coccidiosis by the continual introduction of new drugs or by the use of drug programmes involving rotational use of anticoccidial agents of different biochemical structures either during the grow-out period (shuttle programmes) or at frequent intervals (rotation programmes). In spite of the routine use of anticoccidial agents in poultry feeds, subclinical coccidiosis is still found on the majority of poultry farms. Further the use of anticoccidial drugs adds significantly to the costs of poultry production. It would be an advantage if the amounts of such anticoccidial agents which presently have to be included in feeds to control coccidiosis could be reduced, or even eliminated entirely.
- WO 93/13786 discloses a formulation of micro-organisms suitable for administration to an animal. The formulation comprises a first micro-organism capable of producing lactic acid in the gastrointestinal tract of the animal, a second micro-organism capable of producing a bactericide to which the other micro-organisms in the formulation are resistant, and a fibre-digesting enzyme or a micro-organism capable of producing a fibre-digesting enzyme such as arabinase and xylanase.
- Accordingly, an object of the present invention is to provide a fresh class of compounds which can be used for the treatment and/or prophylaxis of coccidiosis.
- Accordingly, the present invention provides the use of a carbohydrase for the manufacture of an agent for the treatment and/or prophylaxis of coccidiosis.
- It has most surprisingly been found that the inclusion of a carbohydrase in the diet of an animal has the effect of treating or preventing coccidiosis. If such an enzyme is included in the diet of an animal, then the amounts of anticoccidial drugs which have previously been routinely incorporated in its diet can be reduced or in some cases omitted entirely.
This enables considerable economic savings to be achieved in view of the relative expense of anticoccidial drugs. - When omitting anticoccidial drugs from an animal's diet, there are several potential further benefits. Thus, it has previously been necessary to withdraw anticoccidial drugs from the animal's diet for a certain period of time prior to slaughter. This ensures that the meat is relatively free from such drugs and so fit for human consumption. In contrast, if anticoccidial drugs are omitted entirely from the animal's normal diet, as may be achieved in accordance with the present invention, then the animal can be slaughtered at any age rather than after a certain withdrawal period. This gives the farmer improved flexibility, and removes the risk of poultry becoming infected shortly prior to slaughter. Further, anticoccidial drug-residue free meat and eggs can be guaranteed. Such meat and eggs have a market advantage as compared to products which cannot support such a guarantee.
- Even if the enzyme added to the animal's diet only enables the amount of anticoccidial drugs to be reduced, then the overall cost of controlling coccidiosis will be reduced. Synergy or potentiation may extend the useful life of the anticoccidial drug.
- In a further aspect of the present invention, one or more carbohydrases may be included in the diet of an animal together with a conventional concentration of anticoccidial drugs. It has been found that this combination gives rise to a particularly advantageous synergy in that the resulting anticoccidial effect is greater than the mere addition of the individual effects of the enzyme(s) and anticoccidial drugs used separately.
- The enzyme can be formulated as a pre-mix together with any other enzymes to be included in the feed. The pre-mix can be added to the raw materials before feed manufacture, during feed manufacture or as a final step once the feed is otherwise ready for use. It is also possible to add the enzyme directly as a liquid to a feed material preformed as pellets or as a mash.
- It is also possible to include the enzyme in the animal's diet by incorporating it into a second (and different) feed or drinking water which the animal also has access to. Accordingly, it is not essential that the enzyme is incorporated into the feed itself, although such incorporation forms a particularly preferred aspect of the present invention.
- If the enzyme is incorporated into the feed, then this preferably comprises at least 25% by weight of a cereal, and more preferably at least 35% by weight of the cereal. The cereal can be any one or more of wheat, rye, triticale, barley, oats, sorghum, rice and maize. It is particularly preferred that the cereal is wheat.
- Although the cereal component of a cereal-based diet constitutes a source of protein, it is usually necessary to include sources of supplementary protein in the diet such as those derived from fishmeal, meatmeal or vegetables. These sources of supplementary protein can constitute up to 50% by weight of the animal feed. Sources of vegetable proteins include at least one of full fat soybeans, rapeseed, canola, soybean meal, rapeseed meal and canola meal.
- If the enzyme is incorporated into the feed, then this is preferably done in a relative amount of 0.00001-10 g of the enzyme protein per kilo of the feed; more preferably 0.0001-1 g/kg; and most preferably 0.001-0.1 g/kg.
- In the case that the enzyme used is a carbohydrase, then this is preferably a polysaccharidase such as a xylanase, a cellulase, an α-amylase or a pectinase. A preferred cellulase is β-glucanase.
- If the polysaccharidase is a xylanase, then this may be obtained from a fungal source such as Trichoderma, Aspergillus, Humicola or Neocallimastix. It is particularly preferred that the xylanase is the low pI xylanase and/or the high pI xylanase obtainable from Trichoderma longibrachiatum such as described in WO 92/06209. Alternatively, the xylanase can also be obtained from a bacterium such as Bacillus, Streptomyces, Clostridium or Ruminococcus. It is also possible that the xylanase may be obtained from a host which has been subjected to genetic manipulation such as by the inclusion of an appropriate gene within a host bacterial or fungal strain.
- According to one preferred aspect of the present invention, the therapeutic agent does not include any non-enzymic anticoccidial agent. However, if such an agent is present, for instance to counter an outbreak of coccidiosis, then a conventional anticoccidial agent such as salinomycin, monensin, narasin, lasalocid, nicarbazin, maduramycin, nicarbazin and narasin in combination, diclazuril, dinitolmide, halofuginone, robenidine, amprolium or clopidol can be used. Such non-enzymic anticoccidial agents can be included in an animal feed preferably in an amount of 0-100 ppm, and more preferably 0-50 ppm. The latter amount in particular is well below the normal amounts of 50-200 ppm used for the majority of anticoccidial agents included in animal feeds.
- This provides one of the advantages of the present invention of economic savings resulting from the use of lower amounts than is conventional of such relatively costly anticoccidial agents.
- As mentioned above, it is preferred that the agent provided by the present invention is in the form of an animal feed. A suitable feed can be obtained by preparing a pre-mix of the carbohydrase on a cereal carrier, and then adding an appropriate amount, e.g. 1 part by weight, of this pre-mix to 1000 parts by weight of a conventional animal feed.
- Coccidiosis can be treated or prevented in accordance with the present invention in a variety of livestock. Thus, the enzyme of the present invention can be provided in the form of an agent, such as an animal feed, to livestock such as chicken, turkeys, geese, ducks, pigs, sheep or cattle. It is however particularly preferred that the agent is administered to broiler chickens.
- The present invention is further explained by way of the following Examples.
- Four separate groups (A-D), each consisting of ten female Lohmann Brown chicks, were fed the following maize/wheat-based diet for their first twelve days of life:
Maize/wheat-based diet Wheat 25% by weight Maize 42% by weight Soybean meal 20% by weight Fishmeal 10% by weight Vitamin and Mineral Mixture 3% by weight - Each of the groups were then fed the following wheat-based diet for the days 13-21:
Wheat-based diet Wheat 67% by weight Soybean meal 20% by weight Fishmeal 10% by weight Vitamin and Mineral mixture 3% by weight - The diet of the chicks in the groups C and D was supplemented by an enzyme mix including xylanase obtained from Trichoderma Longibrachiatum and β-glucanase also obtained from Trichoderma Longibrachiatum. Thus, a pre-mix containing crude xylanase and crude β-glucanase was prepared and coated on a cereal carrier. This was then added to the above wheat-based feed such that the resulting feeds comprised about 0.0025 g of xylanase protein and about 0.005 g of β-glucanase protein per kg of feed. The diets fed to the chicks in groups A and B were not supplemented with enzymes.
- The chicks in groups B and D were infected with oocysts on day 14. This infection took the form of 5000 E. tenella and 50000 E. acervulina oocysts per chick. The chicks in groups A and C were not infected.
- On day 21, seven days after infection, the chicks were killed and body weight gain and lesion scoring according to the Johnson and Reid system (Exp. Parasitol. (1970) Vol. 28, pp 30-36) in both the duodenum and caecae were undertaken. The results obtained are set out in the following Table 1:
Group Enzyme Infection Average Body Weight gain (g) Lesion Score A - - 89.2 0.00 B - + 42.4 3.78 C + - 91.4 0.00 D + + 63.5 3.00 - It can be understood from the above results that coccidial infection in the group B leads to a significant loss in average body weight gain and a disadvantageous increase in lesions as compared to the control group A. On the other hand, it is clear that when the wheat-based diet of the chicks is supplemented by enzymes in the case of group D, then the effects of coccidial infection are markedly reduced. In particular, the average body weight gain for the chicks in group D is significantly greater than for the chicks in group B. Further, the lesion score for the chicks in group D was lower than the lesion score for the chicks in group B.
- Four groups (E-H), each consisting of twenty Ross male broiler chicks were fed the wheat-based diet set out in the above Example 1 for their first twenty-eight days. The diets of the chicks in groups F and H were supplemented with xylanase obtained from Trichoderma Longibrachiatum. Thus a pre-mix containing crude xylanase was prepared and coated on a cereal carrier. This was then added to the above wheat-based feed such that the resulting feeds comprised about 0.0025 g of xylanase protein per kg of feed. The diets fed to the chicks in groups E and G were not supplemented with xylanase.
- The chicks in groups G and H were infected with oocysts on day 14 in the same manner as the groups B and D were infected in the above Example 1.
- On day 21, seven days after the infection was introduced, the average body weight gain, average feed intake and feed conversion ratio of the chicks in each group were measured. In addition, 10 chicks from each group were killed and their intestinal viscosity measured. These chicks were also subjected to lesion scoring according to the Johnson and Reid system in both the duodenum and caecae. The results are set out in Table 2 below:
Group Enzyme Infection Average Body Weight Gain (g) Average Feed Intake (g) Feed conversion Ratio Lesion Score Viscosity (Pa.s) E - - 318 670 2.11 0 0.0184 F + - 347 670 1.93 0 0.00625 G - + 242 610 2.52 1.9 0.00607 H + + 244 500 2.05 2 0.00266 - The ten remaining chicks in each of the groups E-H were fed for a further seven days, that is for a period ending 14 days after infection. These chicks were then assessed for their average body weight gain, average feed intake and feed conversion ratio. The results obtained are set out in the following Table 3:
Group Enzyme Infection Average Body Weight Gain (g) Average Feed Intake (g) Feed Conversion Ratio E - - 430 920 2.14 F + - 426 880 2.06 G - + 396 740 1.87 H + + 467 940 2.01 - The results set out in Table 2 above indicate that average body weight gain was significantly depressed by coccidial infection with or without enzyme supplementation. On the other hand, the body weight gain for the chicks in group H picked up markedly in the period 7-14 days after infection as can be seen from the results in Table 3.
- From these Tables, it is also clear that there is a negative effect on the feed conversion ratio (FCR) due to coccidial infection. It should be mentioned that the FCR of a feed is the ratio of the amount of feed consumed relative to the weight gain of the animal. A low FCR indicates that a given amount of feed results in a growing animal gaining proportionately more weight. This means that the animal is able to utilise the feed more efficiently. Enzyme addition numerically has a significant impact on the FCR results in Table 2. Thus, the FCR is improved by about 19% in the case of infected birds whose diets are supplemented by the enzymes. In comparison, for birds which are not infected, the FCR of the chicks whose diets are supplemented by enzymes improves only by 8.5% compared to the chicks in the group whose diets are not so supplemented.
- Turning to the results set out in Table 3, it will be seen that body weight gain was substantially increased by enzyme addition in the infected group H as compared to the group G which were not provided with enzyme supplements. This is a most unexpected but advantageous finding. In contrast, it can be seen by comparing the results for groups E and F in Table 3 that the addition of enzyme in the absence of infection has no significant effect.
- The FCR data set out in Table 3 apparently shows the best value for the group G. However, this is misleading because the chicks in this group grow so slowly that they will not meet the required end body weight after the usual growing period, and the economic loss caused by this offsets any advantage in improved feed conversion.
- Ross male broilers were fed the wheat-based feed set out in the above Example 1 for their first 12 days. At Day 12, the birds were randomised by weight into eight groups each containing 20 broilers. These eight groups "I"-"L" were provided with feeds in accordance with the following Table 4:
Group Feed I- Wheat alone J- Wheat + 5 ppm of Cygro K- Wheat + enzyme L- Wheat + enzyme + 5 ppm of Cygro I+ Wheat alone J+ Wheat + 5 ppm of Cygro K+ Wheat + enzyme L+ Wheat + enzyme + 5 ppm of Cygro - In the above Table 4, the feed provided to Group I is the initial wheat-based feed. The feeds provided to Groups J and L are each supplemented with 5 ppm of Maduramycin (the recommended level of inclusion) which is an anti-coccidial ionophore marketed as Cygro by Cyanamid. The enzyme which is included in each of the feeds provided to Groups K and L is a xylanase obtained from Trichoderma longibrachiatum. This is added as a pre-mix, which contains 0.375% of xylanase protein, to the feed in an amount of 0.6 g of the pre-mix per kg of the feed.
- At Day 14, the four "+" groups were orally infected with 50,000 oocysts of E. acervulina and 5,000 oocysts of E. tenella. Feed conversion ratios (for some groups) and lesion scores were measured. The results for the measurement of the feed conversion ratios during the trial are set out in the following Table 5:
Group Day 0 to 7 Days 7 to 14 Days 0 to 14 I- 2.27 2.85 2.49 K- 2.49 2.94 2.67 I+ 2.63 2.48 2.56 K+ 2.51 2.11 2.50 - From the above results, it will be seen that the inclusion of the enzyme in the feed provided to Group K+ improved the feed conversion ratio over the critical 7 day period following infection compared to Group I+ fed the unsupplemented wheat diet. This effect was sustained throughout the duration of the trial.
- Seven days after infection, 10 birds from each group were killed and examined for lesions caused by E. acervulina and E. tenella according to the method of Johnson & Reid. The results obtained are set out in the following Table 6:
Group E. acervulina E. tenella I- 0 0 J- 0 0 K- 0 0 L- 0 0 I+ 2.5 2.6 J+ 2.2 2.2 K+ 2.1 2.8 L+ 2.0 1.7 - From the results set out above, it can be seen that lesion scores for E. acervulina were significantly lower for groups whose feeds were supplemented with the enzyme as compared to the closest comparable control groups. The inclusion of the enzyme in the feeds improved the lesion scores and also gave rise to a further improvement when used in combination with the anti-coccidial agent. The lesion scores caused by E. tenella did not improve on enzyme supplementation alone compared to the unsupplemented wheat diet. On the other hand, the presence of the enzyme did significantly improve the performance of the anti-coccidial agent as can be seen from a comparison between Groups J+ and L+.
- Ross male broilers were fed the wheat-based feed set out in the above Example 1 for their first 12 days. At Day 12, the birds were randomized by weight into two groups each containing 66 broilers. These two Groups "M" and "N" were provided with feeds as follows.
- The feed of Group N was the initial wheat-based diet without any supplementation. The feed of Group M was the same feed supplemented with a xylanase enzyme obtained from Trichoderma longibrachiatum. This enzyme was added as a pre-mix containing 0.187 % of xylanase protein to the feed in an amount of 1 g of the pre-mix per kg of the feed. The pre-mix also included a protease obtained from Bacillus sp. This is present in the pre-mix in an amount of 0.06% of protease protein.
- At Day 14, the two groups were orally infected with 30,000 oocysts of E. acervulina, 15,000 oocysts of E. maxima and 3,000 oocysts of E. tenella. Seven days after infection, birds from each group were killed and examined for lesions caused by E. acervulina, E. maxima and E. tenella according to the method of Johnson & Reid. The results obtained are illustrated in the following Table 7:
Diet Lesion Score E. acervulina Lesion Score E. maxima Lesion Score E. tenella Group N 1.8 0.8 2.5 Group M 1.8 0.6 1.7 - From these results, it can be seen that lesion scores were reduced in Group M fed the enzyme supplemented feed in the case of lesions caused by both E. maxima and E. tenella.
- The effect demonstrated above of treating coccidiosis in the case of wheat-based diets can also be obtained in feeds based on rye, triticale, barley, oats, sorghum, rice or maize. Further, similar results can be obtained when feeds incorporating enzyme supplementation in accordance with the present invention are fed to other animals infected or infectable by coccidiosis such as turkeys, geese, ducks, pigs, sheep and cattle.
Claims (8)
- Use of a carbohydrase for the manufacture of an agent for the treatment and/or prophylaxis of coccidiosis.
- Use according to Claim 1, wherein the agent is in the form of an animal feed.
- Use according to Claim 2, wherein the animal feed comprises at least 35% by weight of cereal.
- Use according to Claim 3, wherein the cereal is wheat.
- Use according to Claims 2-4, wherein the feed further comprises fishmeal, meatmeal or a vegetable protein as a supplemental source of protein.
- Use according to any of Claims 2-5, wherein the animal feed comprises 0.00001-10 g/kg of carbohydrase protein.
- Use according to any preceding Claim, wherein the carbohydrase is one or more polysaccharidases.
- Use according to Claim 7, wherein the polysaccharidase is a xylanase, a cellulase, an α-amylase or a pectinase.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9409336A GB9409336D0 (en) | 1994-05-10 | 1994-05-10 | Use of an enzyme for manufacturing an agent for the treatment and/or prophylaxis of coccidiosis |
| GB9409336 | 1994-05-10 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| EP0681787A2 EP0681787A2 (en) | 1995-11-15 |
| EP0681787A3 EP0681787A3 (en) | 1996-10-23 |
| EP0681787B1 true EP0681787B1 (en) | 2001-10-31 |
Family
ID=10754898
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP95106817A Expired - Lifetime EP0681787B1 (en) | 1994-05-10 | 1995-05-05 | Use of an enzyme for manufacturing an agent for the treatment and/or prophylaxis of coccidiosis |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US5624678A (en) |
| EP (1) | EP0681787B1 (en) |
| DE (1) | DE69523506T2 (en) |
| ES (1) | ES2164724T3 (en) |
| GB (1) | GB9409336D0 (en) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW409035B (en) * | 1997-06-04 | 2000-10-21 | Gist Brocades Bv | Starch-based enzyme granulates |
| GB2327345B (en) | 1997-07-18 | 1999-06-23 | Finnfeeds Int Ltd | Use of an enzyme for manufacturing an agent for controlling bacterial infection |
| AR016969A1 (en) | 1997-10-23 | 2001-08-01 | Procter & Gamble | PROTEASE VARIANTE, ADN, EXPRESSION VECTOR, GUEST MICROORGANISM, CLEANING COMPOSITION, ANIMAL FOOD AND COMPOSITION TO TREAT A TEXTILE |
| GB2358135A (en) * | 1999-12-09 | 2001-07-18 | Finnfeeds Int Ltd | Animal feed additives comprising betaine and a protease |
| US6399123B1 (en) * | 2000-05-25 | 2002-06-04 | University Of Missouri Board Of Curators | Oligosaccharide removal from animal feed |
| BRPI0412279A (en) | 2003-07-02 | 2006-09-19 | Diversa Corp | glucanases, nucleic acids encoding the same and methods for preparing and applying them |
| DK2069389T3 (en) | 2006-08-04 | 2015-01-12 | Bp Corp North America Inc | Glucanases, nucleic acids encoding them, and processes for their preparation and use |
| HUE029140T2 (en) | 2006-09-21 | 2017-02-28 | Basf Enzymes Llc | Phytases, nucleic acids encoding them, and processes for their preparation and use |
| WO2009100456A2 (en) * | 2008-02-08 | 2009-08-13 | Prothera, Inc. | Inhibition and treatment of gastrointestinal biofilms |
| CN106011159A (en) | 2009-05-21 | 2016-10-12 | 巴斯夫酶有限责任公司 | Phytases, nucleic acids encoding them and methods for making and using them |
| GB201311272D0 (en) | 2013-06-25 | 2013-08-14 | Ucl Business Plc | Anti-microbial agents and uses thereof |
| CN114272215B (en) * | 2022-01-04 | 2023-04-07 | 内蒙古通瑞达生物科技有限公司 | Dinitolmide dry suspension and preparation method thereof |
| CN117481253B (en) * | 2023-10-14 | 2026-01-30 | 武汉新华扬生物股份有限公司 | A feed additive and compound feed for preventing coccidiosis infection in broilers |
| WO2025085377A1 (en) * | 2023-10-16 | 2025-04-24 | Zoetis Services Llc | Use of zoalene in livestock |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3492398A (en) * | 1965-08-27 | 1970-01-27 | Monsanto Co | Aminopolyamide resin coating for biologically active substances |
| US3683069A (en) * | 1970-02-19 | 1972-08-08 | Michel Hooreman | Enzymatic products which optimize the viscosity of mucuses and their applications |
| US3932619A (en) * | 1973-02-01 | 1976-01-13 | Eli Lilly And Company | Metabolite A-27106 and processes for its preparation and use |
| JPS5843922A (en) * | 1981-09-10 | 1983-03-14 | Asahi Chem Ind Co Ltd | Anticoccidial agent for domestic fowl |
| US5314692A (en) * | 1987-08-24 | 1994-05-24 | Cultor Ltd. | Enzyme premix for feed and method |
| EP0395294A3 (en) * | 1989-04-25 | 1991-05-22 | Takeda Chemical Industries, Ltd. | Control of protozoal disease |
| JP3608620B2 (en) * | 1990-05-29 | 2005-01-12 | ケムジエン・コーポレイシヨン | Hemicellulase supplements to improve the energy efficiency of hemicellulose-containing foods and animal feed |
| JP2897410B2 (en) * | 1990-11-15 | 1999-05-31 | 味の素株式会社 | Preventive and therapeutic agent for chicken coccidiosis |
| WO1993001800A1 (en) * | 1991-07-24 | 1993-02-04 | Thomas Sai Ying Ko | Therapeutic compositions and methods |
| GB9200891D0 (en) * | 1992-01-16 | 1992-03-11 | Mann Stephen P | Formulation of microorganisms |
-
1994
- 1994-05-10 GB GB9409336A patent/GB9409336D0/en active Pending
-
1995
- 1995-05-05 ES ES95106817T patent/ES2164724T3/en not_active Expired - Lifetime
- 1995-05-05 DE DE69523506T patent/DE69523506T2/en not_active Expired - Lifetime
- 1995-05-05 EP EP95106817A patent/EP0681787B1/en not_active Expired - Lifetime
- 1995-05-10 US US08/435,946 patent/US5624678A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| US5624678A (en) | 1997-04-29 |
| EP0681787A3 (en) | 1996-10-23 |
| ES2164724T3 (en) | 2002-03-01 |
| DE69523506D1 (en) | 2001-12-06 |
| DE69523506T2 (en) | 2002-05-08 |
| EP0681787A2 (en) | 1995-11-15 |
| GB9409336D0 (en) | 1994-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12364719B2 (en) | Bacillus subtilis strains improving animal performance parameters | |
| EP1539224B1 (en) | Antimicrobial composition and method for use | |
| KR100730604B1 (en) | Animal Feed Additives | |
| US5624678A (en) | Method and composition for treatment and/or prophylaxis of coccidiosis | |
| AU2009325106A1 (en) | Compositions and methods for controlling disease in animals | |
| US20220133816A1 (en) | Feed additive formulation and methods of making and using the same | |
| EP0999851B1 (en) | Use of an enzyme for the manufacture of an agent for controlling bacterial infection | |
| Caldas et al. | Effect of an exogenous protease in association with carbohydrases in broilers infected with Coccidia | |
| Botlhoko | Performance of Clostridium perfringens-challenged broilers inoculated with Effective Microorganisms | |
| HK1161293A (en) | Compositions and methods for controlling disease in animals | |
| MXPA00000614A (en) | Use of an enzyme for the manufacture of an agent for controlling bacterial infection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): BE CH DE DK ES FR GB IE IT LI NL SE |
|
| PUAL | Search report despatched |
Free format text: ORIGINAL CODE: 0009013 |
|
| AK | Designated contracting states |
Kind code of ref document: A3 Designated state(s): BE CH DE DK ES FR GB IE IT LI NL SE |
|
| 17P | Request for examination filed |
Effective date: 19961011 |
|
| RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: FINNFEEDS INTERNATIONAL LTD. |
|
| 17Q | First examination report despatched |
Effective date: 19991112 |
|
| GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
| GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
| GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
| GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
| GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
| AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): BE CH DE DK ES FR GB IE IT LI NL SE |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20011031 Ref country code: LI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20011031 Ref country code: CH Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20011031 Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20011031 |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
| REF | Corresponds to: |
Ref document number: 69523506 Country of ref document: DE Date of ref document: 20011206 |
|
| REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
| REG | Reference to a national code |
Ref country code: GB Ref legal event code: IF02 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20020131 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20020131 |
|
| REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2164724 Country of ref document: ES Kind code of ref document: T3 |
|
| NLV1 | Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act | ||
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
| PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
| 26N | No opposition filed | ||
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IE Payment date: 20140512 Year of fee payment: 20 Ref country code: GB Payment date: 20140430 Year of fee payment: 20 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20140509 Year of fee payment: 20 Ref country code: IT Payment date: 20140521 Year of fee payment: 20 Ref country code: ES Payment date: 20140411 Year of fee payment: 20 Ref country code: DE Payment date: 20140430 Year of fee payment: 20 |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R071 Ref document number: 69523506 Country of ref document: DE |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R071 Ref document number: 69523506 Country of ref document: DE |
|
| REG | Reference to a national code |
Ref country code: GB Ref legal event code: PE20 Expiry date: 20150504 |
|
| REG | Reference to a national code |
Ref country code: IE Ref legal event code: MK9A |
|
| REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20150724 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20150504 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20150505 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20150506 |